结核病诊治与防控面临的新挑战及应对思考

New challenges and coping strategies in diagnosis, treatment and control of tuberculosis

摘要

在诊断技术和治疗管理手段不断进步的背景下,结核病防控工作在诊断、治疗和长期管理等面临一系列挑战,本文旨在分析当前结核病诊治和管理现状,综合分析结核潜伏感染识别,特定人群预防及治疗和全程管理等环节,探讨以主动发现、风险分层和全流程慢病管理体系为核心的应对思路,以期为推进结核病诊治质量和防控策略优化提供参考。

Abstract

In the context of continuous advancements in diagnostic technology and treatment management, the prevention and control of tuberculosis are confronted with a series of challenges in diagnosis, treatment, and long term management. Based on a systematic analysis of the current situation of tuberculosis diagnosis, treatment, and management, this paper integrates the management of latent infection, comorbidity management, and information support. It aims to explore the core response concepts of active detection, risk stratification, and a whole-process chronic disease management system, so as to offer references for enhancing the quality of tuberculosis diagnosis and treatment and optimizing the prevention and control strategy.

关键词

结核病 / 耐药 / 潜伏感染 / 诊断 / 治疗

Key words

tuberculosis / drug-resistant / latent infection / diagnosis / treatment

参考文献

[1] World Health Organization. Global tuberculosis report 2025[R]. Geneva: World Health Organization, 2025.

[2] 蒙志好, 吕建楠. HIV/AIDS患者合并结核分枝杆菌感染综合治疗进展[J]. 中国艾滋病性病, 2024, 30(1): 94-97.

[3] Chesov D, Reimann M, Mukherjee T, et al. High rates of acquired resistance to fluoroquinolones, bedaquiline, and linezolid in patients failing treatment against drug-resistant tuberculosis in the Republic of Moldova[J]. Clin Microbiol Infect, 2026, 32(1): 177-180.

[4] 娄思玉, 吴霞, 杨丹, 等. 遵义地区肺结核耐药特征及利福平耐药影响因素分析[J]. 遵义医科大学学报, 2024, 47(5): 495-501.

[5] Inbaraj L R, Srinivasalu V A, Sathya Narayanan M K, et al. Diagnostic accuracy of low-complexity, manual nucleic acid amplification tests for the detection of pulmonary and extrapulmonary tuberculosis in adults and adolescents: a systematic review and meta-analysis[J]. Lancet Microbe, 2025, 6(10): 101169.

[6] 邱勇, 权卓, 屈榕, 等. 县级实验室结核病检测方法的诊断效果分析:一项基于真实世界数据的回顾性研究[J]. 中国防痨杂志, 2025, 47(2): 181-188.

[7] Luukinen B, Ahava M, Aittoniemi J, et al. Diagnostic performance of Xpert MTB/RIF ultra assay with pulmonary and extrapulmonary specimens: a retrospective evaluation in a low-incidence setting in Finland[J]. Clin Microbiol Infect, 2026, 32(1): 87-94.

[8] Ludi Z, Sule A A, Samy R P, et al. Diagnosis and biomarkers for ocular tuberculosis: from the present into the future[J]. Theranostics, 2023, 13(7): 2088-2113.

[9] Kaul S, Kaur I, Mehta S, et al. Cutaneous tuberculosis. Part I: pathogenesis, classification, and clinical features[J]. J Am Acad Dermatol, 2023, 89(6): 1091-1103.

[10] Li N, Zheng H Y, Li W, et al. Limited restoration of T cell subset distribution and immune function in older people living with HIV-1 receiving HAART[J]. Immun Ageing, 2025, 22(1): 3.

[11] Kim S, Can M H, Agizew T B, et al. Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: an individual patient data meta-analysis[J]. PLoS Med, 2025, 22(1): e1004502.

[12] Zein-Eddine R, Refrégier G, Cervantes J, et al. The future of CRISPR in Mycobacterium tuberculosis infection[J]. J Biomed Sci, 2023, 30(1): 34.

[13] Chen P, Yu Y, Zhang Y, et al. Non-targeted metabolomics and machine learning reveal metabolic dysregulation in lymph node tuberculosis[J]. Talanta, 2026, 297(Pt A): 128583.

[14] Ren W, Zhou Y, Li H, et al. Development and clinical evaluation of a CRISPR/Cas13a-based diagnostic test to detect Mycobacterium tuberculosis in clinical specimens[J]. Front Microbiol, 2023, 14: 1117085.

[15] 吕平欣, 刘宇红, 侯代伦, 等. 胸部影像学检查人工智能辅助读片技术在肺结核患者发现中的应用专家共识[J]. 中国预防医学杂志, 2025, 26(9): 1025-1036.

[16] World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: treatment and care[M]. Geneva: World Health Organization, 2025.

[17] 史珂, 代金芳, 李强, 等. 敏感肺结核患者强化期痰培养延迟阴转的危险因素分析[J]. 遵义医科大学学报, 2025, 48(3): 274-279.

[18] 吴小艳, 郑巧, 王杭, 等. 基于哈顿模型的耐多药肺结核不良治疗转归的临床特征及影响因素分析[J]. 遵义医科大学学报, 2025, 48(9): 938-944.

[19] Xu A Y, Velásquez G E, Zhang N, et al. Pyrazinamide safety, efficacy, and dosing for treating drug-susceptible pulmonary tuberculosis: a phase 3, randomized controlled clinical trial[J]. Am J Respir Crit Care Med, 2024, 210(11): 1358-1369.

[20] Ali M Z, Dutt T S, MacNeill A, et al. A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides[J]. eLife, 2024, 13: RP96190.

[21] Sinha A, Klebe R, Rekart M L, et al. The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings-a prospective cohort study in belarus and uzbekistan[J]. Clin Infect Dis, 2025, 81(4): 838-845.

[22] Günther G, Guglielmetti L, Leu C, et al. Availability and costs of medicines for the treatment of tuberculosis in Europe[J]. Clin Microbiol Infect, 2023, 29(1): 77-84.

[23] 王泊宁, 阮云洲, 竺丽梅, 等. 2016-2022年江苏、浙江、上海三省份耐药结核病防治工作效果的监测分析[J]. 疾病监测, 2023, 38(11): 1307-1312.

[24] 王明栋, 夏凤琼, 曹先进, 等. 贵州省结核分枝杆菌对贝达喹啉敏感性及分子突变特征[J]. 中华结核和呼吸杂志, 2025, 48(6): 519-526.

[25] 杨子仪, 陈素婷. 贝达喹啉耐药及耐药诊断的研究进展[J]. 中国防痨杂志, 2025, 47(3): 374-379.

[26] 张玉, 侯双翼, 杨成凤, 等. 湖北省耐多药结核病短程化疗效果及直接医疗费用分析[J]. 中国预防医学杂志, 2025, 26(5): 623-627.

[27] 严天心, 马文斌, 王嘉, 等. 2010-2023年中国肺结核合并症患者治疗依从性及治疗结局影响因素分析[J]. 中国防痨杂志, 2025, 47(10): 1268-1278.

[28] Jing W, Zong Z, Tang B, et al. Population pharmacokinetic analysis of isoniazid among pulmonary tuberculosis patients from China[J]. Antimicrob Agents Chemother, 2020, 64(3): e01736-19.

[29] Conradie F, Bagdasaryan T R, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis[J]. N Engl J Med, 2022, 387(9): 810-823.

[30] 汤秋萍, 廖颖, 徐从睿, 等. 全程管理模式在MDR/RR-TB短程治疗中的应用研究[J]. 湖北科技学院学报(医学版), 2025, 39(6): 515-519.

[31] Wei X, Hicks J P, Zhang Z, et al. Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial[J]. Lancet, 2024, 403(10430): 913-923.

[32] 马艳, 李涛, 王倪, 等. 数字化医疗与结核病防治[J]. 结核病与肺部健康杂志, 2019, 8(4): 233-237.

[33] Chilala C I, Foster N, Bahukudumbi S, et al. Implementation outcomes of tuberculosis digital adherence technologies: a scoping review using the RE-AIM framework[J]. BMJ Glob Health, 2025, 10(2): e016535.

[34] Qin N, Chen J, Chen L, et al. Effectiveness of a mobile health application on treatment outcomes among patients with tuberculosis in Shanghai, China: a multicentre randomised controlled trial[J]. BMJ Glob Health, 2025, 10(6): e018022.

[35] 周林, 初乃惠, 陆伟. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识[J]. 中国防痨杂志, 2021, 43(9): 874-878.

[36] Ling Y, Wang M, Chen S, et al. Prevalence of latent tuberculosis infection in older adults: a systematic review and meta-analysis[J]. Age Ageing, 2025, 54(9): afaf268.

[37] 刘增宾, 刘佳佳, 武娅宁, 等. 慢性非免疫系统性疾病对γ-干扰素释放试验检测结核感染敏感性的影响[J]. 中国防痨杂志, 2025, 47(11): 1481-1488.

[38] Zhou G, Luo S, He J, et al. Risk of progression to active tuberculosis for indeterminate interferon-gamma release assay in immunocompromised individuals: a systematic review and meta-analysis[J]. Clin Microbiol Infect, 2023, 29(11): 1375-1384.

[39] 明瑶, 陈明慧, 王芳, 等. 中国在校生结核分枝杆菌潜伏感染率及预防性治疗意愿的Meta分析[J]. 中国防痨杂志, 2025, 47(12): 1556-1565.

[40] 中国性病艾滋病防治协会HIV合并结核病专业委员会, 张秋月, 陈军, 等. HIV/AIDS患者合并结核病诊治专家共识(2025年版)[J]. 中国艾滋病性病, 2025, 31(11): 1278-1286.

基金资助

国家自然科学基金资助项目(81860004)

贵州省科技创新平台科研项目(黔科合平台CPTXM(2025)017)